LIBRIUM

This brand name is authorized in Germany, Ireland, United Kingdom, South Africa

Active ingredients

The drug LIBRIUM contains one active pharmaceutical ingredient (API):

1 Chlordiazepoxide UNII MFM6K1XWDK - CHLORDIAZEPOXIDE HYDROCHLORIDE

Chlordiazepoxide has anxiolytic and central muscle relaxant properties. It has little autonomic activity. Chlordiazepoxide acts as depressant of the central nervous system producing all levels of CNS depression, from mild sedation to hypnosis, to coma depending on the dose. Read about Chlordiazepoxide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIBRIUM Capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05BA02	Chlordiazepoxide	N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives
Discover more medicines within N05BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 01375392, 01375400, 02499357
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 23043, 23066
Country: IE	Health Products Regulatory Authority	Identifier(s): 31550, 72099
Country: ZA	Health Products Regulatory Authority	Identifier(s): F/2.6/214